RIO DE JANEIRO, BRAZIL – The branch in Brazil will have two offices in Rio de Janeiro, said Andrew Pollard, director of the Oxford Vaccine Group in an interview with Globo.
The first, at the Carlos Chagas Institute, will be the team’s base, for research and courses. Another headquarters, for projects carried out in partnership with the Ministry of Health, will be announced this Monday and will be located at the Cultural Center of the Ministry of Health, at Marechal Âncora square.
At Carlos Chagas, research will be carried out completely independent of the government, with funding from other financial institutions, such as one that has already started two weeks ago, on the third dose of the Covid vaccine using the vaccine developed by Clover Biophamaceuiticals.
The institute will also teach two courses, starting in the first semester of 2022, mixing Brazilian and foreign professors.
These courses, still under construction, will be adapted to the reality and needs of Brazilian professionals, as well as internship, which will take into account professional experience in institutions in Oxford, in Brazil, and in Siena, Italy.
The first course will be in partnership with the course on Infectious Diseases that is given in Oxford, and the second, in partnership with the University of Siena, in Italy, is on Vaccinology and Clinical Development.
Sir Andrew Pollard, director of the Oxford Vaccine Group, arrives in Brazil on Monday to finalize the details of the unit and visit the research centers.
In an interview with Globo he stated that the country offers “enormous potential for us to work together with the UK and integrate projects to improve human health”. One of the reasons for choosing the unit here, the first in Latin America, was the partnership in the development of the Oxford/AstraZeneca vaccine.